Ralph Loren, a Boston-based partner in Edwards Wildman's
Intellectual Property Department, weighed in on the US Supreme Court ruling that human genes cannot be patented in Law360. In the article, “Attorneys React To High Court's Gene Patent Ruling
,” Loren said, "The decision in the Myriad case dashed the hopes of some of the biotech industry, although it was not a complete loss for Myriad. The court gave short shrift to the argument that the U.S. Patent Office has been granting patents on isolated DNA for a long time and this should be given deference, holding that it is up to Congress to change the law. All those who obtained patents for isolated DNA should review their portfolios in light of this decision to determine how it affects them."